CPT 82963: Beta Glucosidase Enzyme Activity Measurement

CPT code 82963 denotes a laboratory measurement of beta glucosidase enzyme activity, most often performed on fibroblasts or white blood cells. This enzymatic assay is clinically important for diagnosing and monitoring lysosomal storage disorders and other metabolic conditions where beta glucosidase function is implicated. Nationally, accurate coding for specialized biochemical assays affects laboratory reimbursement, claims processing, and access to confirmatory testing for rare diseases.

Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a focused overview of the clinical context for 82963, expected settings where the test is performed, and the practical coding considerations that influence laboratory billing and policy application.

The publication outlines benchmarks and comparative policy notes relevant to payers listed above, highlights where coverage policies typically apply for enzyme assays, and provides clinical context to help billing staff and laboratory managers align documentation with payer expectations. Data not available in the input for associated taxonomies, ICD-10 pairings, and related procedure codes.

Billing Code Overview

CPT code 82963 represents a laboratory assay for beta glucosidase (glucocerebrosidase) activity measurement. The test quantifies the enzyme level in cellular specimens, commonly using fibroblasts or white blood cells, to assess enzyme deficiency associated with metabolic conditions.

Service type: Laboratory diagnostic assay for enzymatic activity

Typical site of service: Clinical laboratory or specialized molecular/metabolic testing laboratory; specimen collection from outpatient clinic or hospital lab

Data not available in the input for associated taxonomies, ICD-10 diagnoses, and related codes.

Clinical Context

A 6-year-old child presents to a pediatric genetics clinic with progressive hepatosplenomegaly, delayed motor milestones, and recurrent bone pain. The clinician suspects Gaucher disease based on history and physical exam and orders enzymatic testing to confirm decreased beta-glucocerebrosidase (beta glucosidase) activity. A sample of peripheral blood (leukocytes) or cultured skin fibroblasts is collected in the outpatient clinic or at a hospital outpatient phlebotomy service and sent to a clinical reference laboratory. The laboratory analyst performs quantitative measurement of beta glucosidase activity using validated biochemical assays. Results guide confirmation of enzyme deficiency, inform need for genetic testing of the GBA gene, and support authorization for disease-specific therapies and genetic counseling. Typical sites of service include outpatient clinics, hospital outpatient laboratories, and reference commercial laboratories.

Coding Specifications

Modifier	Description	When to Use
`26`	Professional component	Use when billing only the physician or laboratorian interpretation component separate from the technical processing (rare for standalone enzymatic assays).
`52`	Reduced services

Taxonomy Code	Specialty	Notes
2080P0206X	Clinical Pathology	Pathologists who oversee biochemical genetic testing and laboratory interpretation.
207Q00000X	Pediatric Genetics	Clinicians who order testing, interpret results, and manage inherited metabolic disorders.
2085R0202X	Clinical Laboratory	Clinical laboratory professionals who perform enzymatic assays and report results.
207L00000X	Medical Genetics (Physician)	Specialists who coordinate confirmatory genetic testing and treatment planning.

Related Diagnoses

ICD-10 Code	Description	Clinical Relevance
`E75.22`	Gaucher disease	Primary diagnosis associated with decreased beta-glucocerebrosidase activity; enzymatic assay directly used to confirm enzyme deficiency.
`E75.29`	Other sphingolipidosis	Broader category of disorders where differential enzymatic testing of lysosomal enzymes, including beta glucosidase, may be indicated.
`R16.0`	Hepatomegaly	Common clinical finding in Gaucher disease prompting enzyme testing.
`R16.1`	Splenomegaly	Common clinical finding in Gaucher disease prompting enzyme testing.
`M89.9`	Disorder of bone, unspecified	Bone pain and skeletal manifestations are common in Gaucher disease and lead to diagnostic workup including enzyme assays.

Related CPT Codes

CPT Code	Description	Relationship to This Procedure
`82962`	Glucocerebrosidase (beta-glucosidase) assay; qualitative or semiquantitative	May be used for initial screening assays or less quantitative methods in some labs; complements `82963` which is a quantitative measurement.
`81211`	GBA (glucocerebrosidase) (eg, Gaucher disease) gene analysis; full gene sequence analysis	Performed after enzyme deficiency is identified to confirm pathogenic GBA variants and provide definitive molecular diagnosis.
`82728`	Alpha-galactosidase A (Fabry) assay	Other lysosomal enzyme assays often ordered in parallel to evaluate differential diagnoses of lysosomal storage disorders.
`83020`	Hemoglobin; glycosylated (A1C)	Example of a laboratory test commonly performed during metabolic workups or baseline labs in pediatric patients; not specific but often part of broader panels.
`80502`	Drug screen, qualitative; multiple drug classes	Not specific to this procedure but sometimes performed concurrently in comprehensive metabolic or diagnostic evaluations.

OpenPayer

Summary & Overview